Darlene Dobkowski is a freelance medical journalist with a focus on cancer-related topics. She has written for various publications, including Cancer Network, OncLive, CURE Media Group, and Oncology Nursing News. Darlene's work covers a range of subjects, including treatment advancements, patient experiences, and the impact of cancer on various aspects of life.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Darlene Dobkowski's coverage is heavily focused on healthcare and pharmaceutical topics, with a specific emphasis on cancer-related research, treatment, and care. Her articles frequently cite data and include expert commentary. Therefore, she would likely be interested in pitches that offer access to experts in the field of oncology or related areas who can provide insights supported by recent data.
Given her focus on specific medical conditions such as MPN (Myeloproliferative Neoplasms) and CLL (Chronic Lymphocytic Leukemia), she may also be responsive to pitches providing patient perspectives or interviews with individuals directly affected by these conditions.
Although Darlene does not have a specified geographic focus, her coverage seems to encompass international developments in healthcare and pharmaceuticals.
This information evolves through artificial intelligence and human feedback. Improve this profile .
September 14, 2024 By Darlene Dobkowski, MA Fact checked by Spencer Feldman
By: Darlene Dobkowski
High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab.
Author(s): Darlene Dobkowski, MA Fact checked by: Spencer Feldman
By: Darlene Dobkowski
The safety profile of nivolumab/relatlimab/chemotherapy in RELATIVITY-104 was comparable with prior reports of each individual agent.
By: Ashley Chan, Darlene Dobkowski
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.
By: Ashley Chan, Darlene Dobkowski
In patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding lymphedema risk.
September 16, 2024 By Darlene Dobkowski, MA Fact checked by Ashley Chan
September 16, 2024 By Darlene Dobkowski, MA Fact checked by Ashley Chan
Author(s): Darlene Dobkowski, MA Fact checked by: Kristie L. Kahl
September 16, 2024 By Darlene Dobkowski, MA Fact checked by Kristie L. Kahl
(833) 317-6278 